It shouldn't take long for this to  get back on the US market now! 
Wilson DeCamp 
Leesburg, VA 
UCB Brings Neupro Back to All  Patients in Europe 
From the PharmaLive.com News Archive  - Jun. 29, 2009  
European Commission lifts the  treatment restrictions for Neupro®   
Neupro® can be prescribed for all  patients in accordance with the approved 
indications  
Neupro® available again to all  patients with Parkinson's disease   
Neupro® newly available to adult  patients with moderate to severe Restless 
Legs Syndrome  
Brussels (Belgium), 29 June 2009 -  press release, regulated information - 
UCB announced today that Neupro®  (rotigotine transdermal patch) can now be 
prescribed to all patients with  idiopathic Parkinson's disease in Europe 
and is newly available for the  symptomatic treatment of moderate to severe 
idiopathic Restless Legs Syndrome  (RLS) in adults. This follows the decision 
of the European Commission to lift  treatment restrictions on Neupro® in 
line with the recommendation of the  European Medicines Agency (EMEA), issued 
on 29 May 2009. 
"We are delighted that all patients  with Parkinson's disease in Europe can 
once again benefit from continuous drug  delivery and the improvement in 
symptoms that is offered with Neupro® and that,  for the first time, people 
with RLS in Europe will also experience the  advantages of this important 
treatment," said Troy Cox, Senior Vice President  CNS Operations, UCB. 
Since June 2008, Neupro® supply in  Europe has been limited to patients 
already established on the drug while a new  cold-chain storage and 
distribution system was developed to meet the need for  refrigeration of the product 
from manufacturer to patient. Following full  implementation of this system, 
refrigerated stocks of Neupro® are available in  all doses so Neupro® can be 
prescribed by European physicians for all patients  with idiopathic 
Parkinson's disease. 
Neupro® in Parkinson's disease  Parkinson's disease affects over six 
million people worldwide and approximately  three million patients in the seven 
major markets (U.S., Japan, Germany, UK,  France, Italy and Spain). Formulated 
as a once-a-day transdermal patch, Neupro®  continuous drug delivery 
provides stable drug levels in the bloodstream. Neupro®  provides statistically 
significant and clinically relevant improvements in  movement and ability to 
carry out everyday activities in people with early-stage  Parkinson's disease 
and significantly reduces off time and increases on time in  people with 
later stage Parkinson's disease. Neupro® is generally  well-tolerated. Adverse 
drug reactions reported in more than 10% of Parkinson's  patients treated 
with Neupro® are nausea, dizziness, somnolence and application  site 
reactions. 
Neupro® in RLS In August 2008, the  European Commission approved Neupro® 
for the symptomatic treatment of idiopathic  moderate to severe RLS in adults. 
The UK and Germany are the first European  countries to launch Neupro® (1 
mg/24 h, 2 mg/24 h and 3 mg/24 h) in this new  indication. 
RLS affects between 3 and 10% of the  population to some extent. In a 
clinical trial of 458 patients with moderate to  severe RLS, Neupro® (1 mg/24 h, 
2 mg/24 h and 3 mg/24 h dose) proved more  efficacious than placebo in 
relieving bedtime, night and daytime symptoms in  patients over a six month 
treatment period. Neupro® was shown to reduce symptoms  by >=50% in over half of 
patients (54.2%) compared to symptom reduction in  approximately one third 
(29.9%) of patients on placebo. In addition more  patients receiving Neupro® 
(3 mg/24 h) achieved clinical remission (47.3% vs.  22.8% placebo) and 
symptom freedom (31.3% vs. 12.3%  placebo). 
"We look forward to having Neupro®  available as a new treatment option for 
RLS patients. The results of this  rotigotine trial demonstrated efficacy, 
increased opportunity for symptom  freedom in moderate to severely affected 
RLS patients and improvements to  patients' quality of life" said Dr Claudia 
Trenkwalder from the Paracelsus-Elena  Hospital, Kassel, Germany and lead 
investigator of the  study. 
Further information   
Antje Witte, Corporate  Communications & Investor Relations, UCB T 
+32.2.559.9414,  [log in to unmask] 
Michael Tuck-Sherman, Investor  Relations, UCB T +32.2.559.9712,  
[log in to unmask] 
Nancy Nackaerts, External  Communications, UCB T +32.2.559.9264,  
[log in to unmask] 
Eimear O'Brien, Global CNS  Communications Manager, UCB T +32.2.559.9271,  
[log in to unmask]

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn